Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDRNASDAQ:APLSNASDAQ:CORTNASDAQ:DCPHNASDAQ:QURE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/AAPLSApellis Pharmaceuticals$49.69+3.7%$58.21$19.83▼$94.75$5.99B0.881.46 million shs149,546 shsCORTCorcept Therapeutics$22.75+2.4%$23.81$20.84▼$34.28$2.37B0.481.46 million shs45,622 shsDCPHDeciphera Pharmaceuticals$14.31+0.9%$15.61$9.90▼$17.73$1.16B0.39516,744 shs12,177 shsQUREuniQure$4.59+1.1%$5.30$4.35▼$22.48$219.59M0.95958,254 shs25,087 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%APLSApellis Pharmaceuticals-4.01%+0.88%-18.76%-25.16%-43.40%CORTCorcept Therapeutics-1.20%-1.99%-10.26%+2.54%-0.09%DCPHDeciphera Pharmaceuticals-3.01%-0.35%-4.32%-0.56%-1.46%QUREuniQure-0.44%-3.61%-14.66%-22.13%-76.53%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPLSApellis Pharmaceuticals4.4933 of 5 stars4.41.00.04.43.12.50.6CORTCorcept Therapeutics4.778 of 5 stars3.51.00.04.52.53.33.1DCPHDeciphera Pharmaceuticals3.7847 of 5 stars3.42.00.03.82.21.70.6QUREuniQure1.5327 of 5 stars3.42.00.00.00.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDRAlder BiopharmaceuticalsN/AN/AN/AN/AAPLSApellis Pharmaceuticals2.87Moderate Buy$77.9356.84% UpsideCORTCorcept Therapeutics3.00Buy$39.3072.75% UpsideDCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0060.73% UpsideQUREuniQure2.71Moderate Buy$32.00597.17% UpsideCurrent Analyst RatingsLatest APLS, QURE, DCPH, CORT, and ALDR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.004/23/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.004/17/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$67.00 ➝ $57.004/15/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/9/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.003/27/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$60.003/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.003/6/2024APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$78.00 ➝ $79.003/4/2024APLSApellis PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$87.00 ➝ $89.003/4/2024QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $7.003/1/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73APLSApellis Pharmaceuticals$396.59M15.11N/AN/A$1.64 per share30.30CORTCorcept Therapeutics$482.38M4.91$0.97 per share23.47$4.92 per share4.62DCPHDeciphera Pharmaceuticals$163.36M7.08N/AN/A$4.38 per share3.27QUREuniQure$15.84M13.86N/AN/A$4.34 per share1.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/AAPLSApellis Pharmaceuticals-$528.63M-$4.48N/A46.01N/A-133.34%-178.60%-60.41%5/7/2024 (Confirmed)CORTCorcept Therapeutics$106.14M$0.9523.9517.11N/A21.86%21.98%17.89%5/1/2024 (Confirmed)DCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)QUREuniQure-$308.48M-$6.48N/AN/AN/A-1,947.09%-99.31%-37.65%5/14/2024 (Estimated)Latest APLS, QURE, DCPH, CORT, and ALDR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AAPLSApellis Pharmaceuticals-$0.55N/A+$0.55N/AN/AN/A 5/1/2024N/ACORTCorcept Therapeutics$0.18N/A-$0.18N/AN/AN/A 2/28/2024Q4 2023QUREuniQure-$1.54-$1.53+$0.01-$1.53$3.20 million$6.69 million2/27/202412/31/2023APLSApellis Pharmaceuticals-$0.73-$0.73N/A-$0.73$143.34 million$146.38 million 2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million 2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDRAlder Biopharmaceuticals1.748.948.94APLSApellis Pharmaceuticals0.483.102.50CORTCorcept TherapeuticsN/A4.394.31DCPHDeciphera PharmaceuticalsN/A3.803.59QUREuniQure0.498.858.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDRAlder BiopharmaceuticalsN/AAPLSApellis Pharmaceuticals96.29%CORTCorcept Therapeutics93.61%DCPHDeciphera Pharmaceuticals70.96%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipALDRAlder Biopharmaceuticals15.40%APLSApellis Pharmaceuticals7.50%CORTCorcept Therapeutics19.80%DCPHDeciphera Pharmaceuticals4.43%QUREuniQure4.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableAPLSApellis Pharmaceuticals702120.58 million111.54 millionOptionableCORTCorcept Therapeutics352104.08 million83.48 millionOptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableQUREuniQure48047.84 million45.90 millionOptionableAPLS, QURE, DCPH, CORT, and ALDR HeadlinesSourceHeadlineuniQure (NASDAQ:QURE) Stock Price Crosses Below 200-Day Moving Average of $6.06americanbankingnews.com - April 19 at 4:58 AMUniQure (QURE) Reports Q4 Loss, Tops Revenue Estimateszacks.com - February 28 at 9:20 AMuniQure Announces 2023 Financial Results and Highlights Recent Company Progressglobenewswire.com - February 28 at 7:05 AMuniQure: The AMT-130 Readoutseekingalpha.com - July 17 at 1:47 PMMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureseekingalpha.com - May 22 at 5:38 PMuniQure: Financials And Pipeline Signal A Promising Outlook For Investorsseekingalpha.com - May 20 at 9:19 AMWhy Sunstar's unique M&A model is attractive to independent agencies - Insurance Businessinsurancebusinessmag.com - February 7 at 2:42 PMUnique new Greenville business hoping to lather up same success of other locations - WNCTwnct.com - February 7 at 2:42 PMNew: The Buffalo Gift Emporium is Expanding its Unique Selection of Gifts - Step Out Buffalostepoutbuffalo.com - February 7 at 2:42 PMMarshall fire victims with no renter's insurance face unique obstacles - The Colorado Suncoloradosun.com - February 7 at 2:42 PM'Chess on ice:' Curling classes give Olympic viewers chance to try unique sport in Grand Rapids - MLive.commlive.com - February 7 at 2:42 PMReview: Bittersweet, quirky 'Sapience' takes unique look at the hurdles of communication - The San Diego Union-Tribunesandiegouniontribune.com - February 7 at 2:42 PMHappy Rose Day: 5 Unique Rose Recipes You Can Make For Loved Ones - NDTV Foodfood.ndtv.com - February 7 at 9:41 AMUnique partnership solves UP bridge problem | News, Sports, Jobs - Escanaba Daily Pressdailypress.net - February 7 at 9:41 AMGeneva's Little Traveler to celebrate 100 years of unique shopping experience - Shaw Localshawlocal.com - February 7 at 9:41 AMPenguins duo unveils unique NIL deal with Austintown business - Warren Tribune Chronicletribtoday.com - February 7 at 9:41 AMDozens of unique vendors set up shop for Craft Fair - Marshalltown Times Republicantimesrepublican.com - February 7 at 9:41 AMUnique math class helps students build their futures - FOX 31 Denverkdvr.com - February 7 at 9:41 AMA DoSeum experience as unique as you and me - San Antonio Reportsanantonioreport.org - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireglobenewswire.com - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Diseasefinance.yahoo.com - February 7 at 9:41 AM'Cats on Mats' gives Bloomington adoption event a unique twist - HOI ABChoiabc.com - February 6 at 8:12 AMWould You Ride...These Crazy Unique Roller Coasters? - Theme Park Touristthemeparktourist.com - February 6 at 3:12 AM'Cats on Mats' gives Bloomington adoption event a unique twist - week.comweek.com - February 6 at 3:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackAll Headlines Company DescriptionsAlder BiopharmaceuticalsNASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Apellis PharmaceuticalsNASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Deciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.uniQureNASDAQ:QUREuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.